Synapse - Early Drug Development Service

Results (464)

Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

Meeting Abstract

Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)

Meeting Abstract

Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing

Meeting Abstract

Heredia, J. B.; Diplas, B. H.; El Nahhas, O. S. M.; Selenica, P.; Pareja, F.; Mandelker, D.; Weigelt, B.; Riaz, N.; Rosen, E.; Sfeir, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers

Meeting Abstract

Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
Annals of Oncology (2023)

Fulltext@MSK | Save

EZH2 inhibition: It's all about the context

Editorial

Rosen, E. Y.; Shukla, N. N.; Glade Bender, J. L.
JNCI: Journal of the National Cancer Institute (2023)

Fulltext@MSK | Save

Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma

Journal Article

Mandelker, D.; Marra, A.; Zheng-Lin, B.; Selenica, P.; Blanco-Heredia, J.; Zhu, Y.; Gazzo, A.; Wong, D.; Yelskaya, Z.; Rai, V.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

Meeting Abstract

McKean, M.; Spira, A. I.; Rosen, E.; Subbiah, V.; Moreno, V.; Gambardella, V.; Vieito, M.; Saavedra, O.; Cousin, S.; Cassier, P. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma

Meeting Abstract

Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors

Meeting Abstract

Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions

Meeting Abstract

Chen, M. F.; Yang, S. R.; Tao, J.; Desilets, A.; Rosen, E.; Gong, Y.; Mullaney, K. A.; Kris, M. G.; Arcila, M. E.; Donoghue, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save